Bayer has told U.S. lawmakers it could stop selling Roundup weedkiller unless they can strengthen legal protection against ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

The rebuilding of its pharmaceuticals pipeline comes as Bayer faces fading earnings of blockbuster blood-thinning drug ...

Bayer's CEO is facing increasing investor pressure to deliver on turnaround efforts and reverse a forecast earnings decline ...

Bayer has told U.S. lawmakers it could stop selling Roundup weedkiller unless they can strengthen legal protection against ...

The company expects improved performance from 2026 onwards. Alongside its four existing strategic priorities, the company is adding ...